

SERENATIS: Three novel therapeutics for treating OCD

Contact: Nick Sireau, CEO, nick@serenatisbio.com

Revolutionising OCD with Three Breakthrough Treatments

- Serenatis is developing three novel small-molecule drugs, each with a unique mechanism of action targeting different pathways implicated in OCD, including the glutamate and dopamine systems.
- These innovative therapies aim to address the root causes of OCD and offer new hope for patients through precision medicine.
- These game-changing treatments have the potential to generate blockbuster sales, forecasted at \$4.5 billion at peak.
- Despite affecting over 240 million people worldwide (3% of the population), OCD remains a misunderstood and debilitating mental illness with limited treatment options.
- As Big Pharma renews its interest in neuroscience, our assets present attractive acquisition targets with significant upside potential.

Our Pipeline: Three Novel Approaches to Treating OCD

SB001:

- A novel mGluR2 modulator targeting the imbalance of glutamate and GABA in OCD.
- Proven safety in Phase 1 trials, ready to enter clinical trials.
- Strong potential for fast-tracking due to derisked safety profile.

SB002

- Modulates AMPA and enhances neuroplasticity - proven approach in OCD treatment.
- A promising candidate with a derisked safety profile and preclinical and clinical validation.

SB003

- A novel COMT inhibitor regulating dopamine in the prefrontal cortex.
- Shown to reduce OCD symptoms in clinical settings.
- Strong therapeutic potential backed by advisor Prof. Jon Grant's research.

We will use a precision medicine approach using EEG and genetic biomarkers to identify which patients respond best to which drugs.

Why Invest Now?

OCD is not only a massive market opportunity but also one of the most disabling medical disorders according to the World Health Organization. Existing treatments, including high doses of SSRIs and cognitive behavioural therapy, leave a large portion of patients unresponsive, with many experiencing significant side effects or no relief at all.

Serenatis Bio offers investors the chance to back a highly differentiated approach with a clear path to commercialisation. Our drugs address the root causes of OCD, providing a potentially life-changing solution for millions of patients worldwide.

Beyond OCD: Future Expansion

Our innovative compounds hold promise beyond OCD. They have the potential to address related disorders such as body dysmorphic disorder, excoriation disorder, trichotillomania, pathological gambling, and certain anxiety disorders, opening further commercial opportunities.

Backed by a World-Class Team

- **David Cavalla, PhD (Executive Chairman):** A world leader in drug development and repurposing.
- **Nick Sireau, PhD (CEO):** A patient advocate with personal experience in OCD and a proven track record in drug development.
- **Prof. Jon Grant, MD (Clinical Advisor):** Director of the University of Chicago's clinic on compulsive disorders, and a key thought leader in OCD research and clinical trials.
- **Ekaterina Malievskaia, MD (Advisor):** Co-founder of COMPASS Pathways, with extensive experience in clinical innovation and trial design.
- **Prof Trevor Robbins (Scientific Advisor):** Prof Cognitive Neuroscience, University of Cambridge, and OCD expert.
- **Julia Jones (CFO):** Chartered Accountant, formerly at PwC

A Compelling Investment Opportunity

We are raising **\$1.3 million in our pre-seed** round to advance preclinical work on our three novel compounds. We have a lead VC confirmed, a signed term sheet, and are looking for co-investors to join the syndicate.

These NCE drugs are being tested in the SAPAP3 mouse model of OCD—a widely respected and validated model in the field. With encouraging data, we aim to rapidly move our candidates into clinical development.

